ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

12,402Medicare Part D Prescriptions Filled, Including Refills

Rank: 251 out of 6969

$366K Total Retail Price of All Prescriptions

Rank: 1115 out of 6969

458 Patients Receiving at Least One Drug in Part D
92%Patients 65 Years and Older
46% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in California
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

13% of this provider’s 458 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 11,460 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

13% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$30 was the average price of a prescription from this provider, compared to $57 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in California
BENAZEPRIL HCL 895 837 10 1 18
SIMVASTATIN 865 806 2 1
LOVASTATIN 541 501 3 15
OMEPRAZOLE 524 481 4 6
HYDROCHLOROTHIAZIDE 523 502 5 8
FELODIPINE ER 483 480 10 6 116
AMLODIPINE BESYLATE 469 446 7 4
METFORMIN HCL 417 371 8 7
LISINOPRIL 416 382 9 2
ATENOLOL 341 299 10 9
GLIPIZIDE 319 301 11 21
LEVOTHYROXINE SODIUM 300 276 12 5
DOXAZOSIN MESYLATE 243 231 13 74
ALENDRONATE SODIUM 182 176 14 14
GLIMEPIRIDE 156 149 15 44
LOSARTAN POTASSIUM 153 134 16 12
RANITIDINE HCL 146 131 17 46
HYDROCODONE-ACETAMINOPHEN 145 139 S3 18 3
METOPROLOL TARTRATE 141 135 19 13
FINASTERIDE 136 136 20 80
PAROXETINE HCL 134 122 21 65
FUROSEMIDE 121 102 22 10
HYDRALAZINE HCL 121 111 22 106
DONEPEZIL HCL 120 114 24 32
ATORVASTATIN CALCIUM 118 118 25 11
ACARBOSE 117 108 26 246
DICLOFENAC SODIUM 117 103 26 78
GLYBURIDE-METFORMIN HCL 107 95 R 28 92
TRIAMTERENE-HCTZ 99 95 29 58
GABAPENTIN 95 95 30 17
CLONIDINE HCL 94 94 31 59
JANUVIA 81 81 32 41
ZOLPIDEM TARTRATE 74 73 33 16
INSULIN SYRINGE 74 69 33 60
CITALOPRAM HBR 73 71 35 34
ENALAPRIL MALEATE 71 59 36 56
TAMSULOSIN HCL 70 63 37 23
DIOVAN 65 65 38 26
IBUPROFEN 65 56 38 29
FLUTICASONE PROPIONATE 63 53 40 24
HUMULIN 70-30 60 52 41 294
TRAMADOL HCL 60 59 41 27
PANTOPRAZOLE SODIUM 57 50 43 31
CARVEDILOL 56 40 44 25
LANTUS 54 48 45 50
VENLAFAXINE HCL ER 54 54 45 150
GLIPIZIDE ER 54 54 45 199
AZITHROMYCIN 52 43 48 42
METOPROLOL SUCCINATE 51 51 49 22
FLUNISOLIDE 51 48 49 475
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 13, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.